An Update on Scientific Advances and Clinical Strategies in Idiopathic Pulmonary Fibrosis

The European Respiratory Society (ERS) International Congress 2017 was held in Milan, Italy, September 9-13, 2017. The Congress has been a platform for improving standards in respiratory medicine and putting the spotlight on respiratory care. In this activity, 2 experts summarize the key learnings from this year’s Congress focusing on Idiopathic Pulmonary Fibrosis (IPF).

TARGET AUDIENCE

This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with IPF.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants will be better able to do the following:

  1. Identify recent advances in the understanding of IPF pathophysiology, genetics, disease progression, and comorbidities
  2. Discuss recent advances in IPF treatment

FACULTY

Fernando J. Martinez, MD, MS
Chief
Pulmonary and Critical Care Medicine
Bruce Webster Professor of Medicine
Joan and Sanford I. Weill Department of Medicine
Weill Cornell Medical College
New York-Presbyterian Hospital/Weill Cornell Medical Center
New York, New York

Steven D. Nathan, MD
Professor of Medicine
Virginia Commonwealth University-Inova Campus
Director
Advanced Lung Disease Program
Inova Fairfax Hospital
Falls Church, Virginia

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

FacultyRelationship Identified With:
Fernando J. Martinez, MD, MS

Consultant/Advisor: AstraZeneca, Boehringer Ingelheim GmbH, Genentech, Inc., GlaxoSmithKline LLC, Novartis AG, Pearl Therapeutics, Inc., Protexin, Theravance Biopharma

Grant/Research Support: AstraZeneca, Boehringer Ingelheim GmbH, GlaxoSmithKline LLC

Speakers’ Bureau: Boehringer Ingelheim GmbH, Miller Pharmacal Group, Inc., NACE International, Novartis AG, UpToDate, Inc., WebMD, LLC

Steven D. Nathan, MD

Consultant/Advisor: Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd, Genentech, Inc.

Grant/Research Support: Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd, Genentech, Inc.

Speakers’ Bureau: Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd, Genentech, Inc.

Non-faculty: Lyerka Miller, PhD; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD, hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC.

CME Credit (Physicians)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Miller Medical Communications, LLC., and Boehringer Ingelheim Pharmaceuticals, Inc., do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Course opens: 
12/08/2017
Course expires: 
12/07/2018
Rating: 
0

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician

Accreditation Period

Course opens: 
12/08/2017
Course expires: 
12/07/2018
Please login or register to take this course.